Small cell lung cancer · 5 regimens
Cost vs Efficacy · 3 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Pembrolizumab monotherapy Variant #01 | — | R 286 955 | 14d | ~7.1 mo | ~20.3 mo | ~16 | ~R 4 591 284 PFS proxy · indirect | 13 |
Ipilimumab and Nivolumab Variant #01 Partial | — | R 78 615 | 42d | ~11.5 mo | ~29.2 mo | ~9 | ~R 707 538 PFS proxy · indirect | 13 |
CDE Variant #04 | — | R 2 810 | 21d | ~4.9 mo | ~12.4 mo | ~8 | ~R 22 477 PFS proxy · indirect | — |
Best supportive care Partial | — | — | — | — | ~3.2 mo | — | — | 1 |
Nivolumab monotherapy Variant #01 Partial | — | — | 14d | — | 7.5 mo | — | — | 1 |
5 of 5 regimens shown